First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

BACKGROUND: New options for first-line treatment of human immunodeficiency virus type 2 (HIV-2) infection are needed. We evaluated an integrase inhibitor (raltegravir)–containing regimen. METHODS: Antiretroviral therapy (ART)–naive adults with symptomatic infection by HIV-2 only, CD4 count <500 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Matheron, Sophie, Descamps, Diane, Gallien, Sebastien, Besseghir, Amel, Sellier, Pierre, Blum, Laurent, Mortier, Emmanuel, Charpentier, Charlotte, Tubiana, Roland, Damond, Florence, Peytavin, Gilles, Ponscarme, Diane, Collin, Fideline, Brun-Vezinet, Francoise, Chene, Genevieve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160602/
https://www.ncbi.nlm.nih.gov/pubmed/29590335
http://dx.doi.org/10.1093/cid/ciy245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160602/
https://www.ncbi.nlm.nih.gov/pubmed/29590335
http://dx.doi.org/10.1093/cid/ciy245

Ejemplares similares